ANeurotech

ANeurotech

Foundation date

01/12/2018

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Small molecules

Therapeutic areas

• #Diseases of the nervous system

ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, is rolling out, following a successful pre-IND meeting with the US Food and Drug Administration (FDA), its pivotal Phase IIIb development programme of ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder (MDD).

The Phase IIIb will include a secondary endpoint of improvement in cognitive function and the ability to feel pleasure, the first time this has been included in an anti-depression drug clinical trial. ANeuroTech will file for IND in Q4 2022 and apply for FDA Fast-Track Designation at the same time.

More than 60% of people with depression and associated cognitive problems are not helped by initial treatments or experience challenging side-effects.

ANeuroTech is developing ANT-01 as an adjunctive anti-depression drug with minimal or no side-effects. ANT-01 is a low dose of an existing drug substance, pipamperone dihydrochloride, a typical antipsychotic developed by the late Dr Paul Janssen (Founder of Janssen Pharmaceutica which merged with Johnson & Johnson) and marketed for over 40 years in Europe at a high dose range for the treatment of psychotic disorders.

Dr Erik Buntinx, CEO and Founder of ANeuroTech, discovered through his clinical practice that ANT-01 has a unique high selectivity and affinity for the serotonin 5-HT2A and dopamine D4DR brain receptors, and shows potential as an adjunctive treatment with fewer side effects.

The pivotal Phase IIIb development programme will assess the safety and efficacy of a single low (15mg) dose of ANT-01 combined with a first-line antidepressant versus placebo, in MDD patients with insufficient response to selective serotonin re-uptake inhibitor (SSRI) or selective noradrenaline serotonin re-uptake inhibitor (SNRI) treatment. The Phase IIIb follows positive clinical data generated from earlier trials which demonstrated superior antidepressant activity of ANT-01 with a favourable safety profile. The data also showed an improvement in the ability to feel pleasure and in cognitive function, which has not been demonstrated by any other antidepressant molecule. This will be further explored in the Phase IIIb programme, which will recruit 600 patients at a number of US sites and is planned to begin in 2023.

ANeuroTech is led by its highly experienced Executive Partner Team existing of Dr. Erik Buntinx, MD, Fouding CEO & Inventor, Dr. Rudi Pauwels, Executive Chairman and Patrick Verheyen, Chief Executive Business Development.

Together, Erik, Rudi and Patrick are driven by one single mission: bringing ANT-01 to the patients in need for. Patients are waiting.